BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND EML4, ENSG00000143924, 27436 AND Clinical Outcome
18 results:

  • 1. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
    Tabbò F; Muscarella LA; Gobbini E; Trombetta D; Castellana S; Rigutto A; Galetta D; Maiello E; Martelli O; Tiseo M; Scotti V; Ghilardi L; Gregorc V; Sergi C; Pilotto S; Del Conte A; Cappuzzo F; Cortinovis D; Osman G; Bareggi C; Di Maio M; Rossi A; Rossi G; Bria E; Volante M; Scagliotti GV; Graziano P; Novello S; Righi L
    Eur J Cancer; 2022 Oct; 174():200-211. PubMed ID: 36044814
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.
    Yao Y; Yu Z; Ma Y; Ou Q; Wu X; Lu D; Li X
    ESMO Open; 2022 Apr; 7(2):100405. PubMed ID: 35305401
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
    Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
    Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. clinical significance of ROS1 5' deletions in non-small cell lung cancer.
    Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
    Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with clinical outcomes.
    Couëtoux du Tertre M; Marques M; Tremblay L; Bouchard N; Diaconescu R; Blais N; Couture C; Pelsser V; Wang H; Higenell V; Izzi L; Gambaro K; Hoffert C; Srivastava A; Spatz A; Rousseau C; McNamara S; Cohen V; Batist G; Agulnik J
    Mol Cancer Ther; 2019 Sep; 18(9):1628-1636. PubMed ID: 31243098
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Impact of eml4-ALK Variant on Resistance Mechanisms and clinical outcomes in ALK-Positive lung cancer.
    Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
    J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
    Koinis F; Voutsina A; Kalikaki A; Koutsopoulos A; Lagoudaki E; Tsakalaki E; Dermitzaki EK; Kontopodis E; Pallis AG; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2018 Feb; 20(2):140-149. PubMed ID: 28631135
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
    Castañón E; Rolfo C; Viñal D; López I; Fusco JP; Santisteban M; Martin P; Zubiri L; Echeveste JI; Gil-Bazo I
    J Transl Med; 2015 Aug; 13():257. PubMed ID: 26248464
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Combined point mutation in KRAS or EGFR genes and eml4-ALK translocation in lung cancer patients.
    Jürgens J; Engel-Riedel W; Prickartz A; Ludwig C; Schildgen O; Tillmann RL; Stoelben E; Brockmann M; Schildgen V
    Future Oncol; 2014 Mar; 10(4):529-32. PubMed ID: 24754584
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
    Chen Z; Akbay E; Mikse O; Tupper T; Cheng K; Wang Y; Tan X; Altabef A; Woo SA; Chen L; Reibel JB; Janne PA; Sharpless NE; Engelman JA; Shapiro GI; Kung AL; Wong KK
    Clin Cancer Res; 2014 Mar; 20(5):1204-1211. PubMed ID: 24327273
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
    Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'.
    Pilotto S; Bonomi M; Massari F; Milella M; Ciuffreda L; Brunelli M; Fassan M; Chilosi M; Scarpa A; Tortora G; Bria E
    Curr Pharm Des; 2014; 20(24):3958-72. PubMed ID: 24138719
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. clinical outcome for eml4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
    Takeda M; Okamoto I; Sakai K; Kawakami H; Nishio K; Nakagawa K
    Ann Oncol; 2012 Nov; 23(11):2931-2936. PubMed ID: 22771825
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer.
    John T; Yanagawa N; Kohler D; Craddock KJ; Bandarchi-Chamkhaleh B; Pintilie M; Sykes J; To C; Li M; Panchal D; Chen W; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Jul; 7(7):1101-8. PubMed ID: 22617243
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
    Ju YS; Lee WC; Shin JY; Lee S; Bleazard T; Won JK; Kim YT; Kim JI; Kang JH; Seo JS
    Genome Res; 2012 Mar; 22(3):436-45. PubMed ID: 22194472
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
    Yuan Y; Liao YM; Hsueh CT; Mirshahidi HR
    J Hematol Oncol; 2011 Apr; 4():16. PubMed ID: 21504625
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Identification of the transforming eml4-ALK fusion gene in non-small-cell lung cancer.
    Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
    Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.